Published 1 year ago • loading... • Updated 1 year ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc., a biotechnology company listed on Nasdaq as IMUX, announced the closing of its underwritten public offering on June 3, 2025, in New York.
The offering arose from Immunic's need to fund clinical trials and operations for its orally administered therapies targeting chronic inflammatory and autoimmune diseases.
This oversubscribed offering included pre-funded warrants and Series B warrants immediately or conditionally exercisable, with co-leads BVF Partners and Coastlands Capital and other institutional investors participating.
Immunic generated around $65 million in initial funds before deductions and stands to gain up to an additional $130 million if all Series A and B Warrants are fully converted through cash payment.
The funding will be used to advance Immunic's leading candidate, vidofludimus calcium , which is undergoing phase 3 clinical testing for relapsing multiple sclerosis, with initial trial results anticipated by the end of 2026.

Insights by Ground AI

42 Articles

Rutland Herald

+38 Reposted by 38 other sources

Center

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

NEW YORK, June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the closing of its…

1 year ago

Read Full Article